10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
When it comes to long-term investment in pharma stocks, looking at pipeline assets at a pre-clinical or early clinical stage gives as good a clue as any as to where the value lies. 17 May 2019
A draft issued on March 29 by China’s National Health Commission (CNHC), which regulates hospitals in China, allows qualified 3 Jia ( meaning top-level) public hospitals to develop and commercialize somatic cell therapies within their own hospitals. 17 May 2019
New Jersey, USA-based Merck & Co has announced it will present 140 abstracts at the upcoming annual meeting of the Annual Society of Clinical Oncology (ASCO), including on the anti-PD-1 blockbuster Keytruda (pembrolizumab) and Lynparza (olaparib) - in over 25 types of cancer. 17 May 2019
Privately-held Parvus Therapeutics has entered into a worldwide collaboration and license agreement with Genentech, a subsidiary of Roche, to develop, manufacture, and commercialize novel Navacim therapeutics for the treatment of inflammatory bowel disease (IBD), autoimmune liver diseases (ALD), and celiac disease (CD). 17 May 2019
A dual kinase inhibitor is entering a clinical trial for advanced pancreatic cancer in combination with the chemotherapy drug gemcitabine as part of an academic-industry initiative supported by the charity Cancer Research UK. 16 May 2019
After a slow start, there have been better recent sales of Yescarta (axicabtagene ciloleucel), the CAR-T therapy that Gilead Sciences picked up in its $11.9 billion acquisition of Kite Pharma in 2017. 16 May 2019
The Roche and AbbVie partnered asset Venclexta (venetoclax) has won US approval in combination with Gazyva (obinutuzumab) as a first-line, chemo-free option in chronic lymphocytic leukemia (CLL). 16 May 2019
US drugmaker Vertex Pharmaceuticals and biotech firm Kymera Therapeutics have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets. 16 May 2019
German pharma major Bayer yesterday announced positive findings from new analyses and data for Vitrakvi (larotrectinib), confirming the efficacy and safety of larotrectinib in patients with TRK fusion cancer. 16 May 2019
Anglo-American pharma Adaptimmune Therapeutics and Seattle-based Alpine Immune Sciences have linked up in designing and developing specific peptide enhanced affinity receptor (SPEAR) T-cell therapies. 15 May 2019
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Biogen’s Spinraza (nusinersen) to treat infants, children and adults with spinal muscular atrophy (SMA). 15 May 2019
Chuikyo, Japan’s Central Social Insurance Medical Council, on May 15 approved the listing of Swiss pharma giant Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) on May 22, with a National Health Insurance (NHI) price tag of some 33.5 million yen ($305,800), according to media reports. 15 May 2019
The USA-based Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s Disease Therapeutics, the fourth in a series on the innovation landscape of highly prevalent, chronic diseases. 15 May 2019
The US Food and Drug Administration (FDA) has approved Bavencio (avelumab) in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC; kidney cancer). 15 May 2019
Swedish Orphan Biovitrum, the Nordic biotech company that is known as Sobi, has bumped its share price up by 5% at its Capital Markets Day 2019. 14 May 2019
Canada’s Zymeworks has entered into a licensing agreement giving Iconic Therapeutics certain rights to its proprietary ZymeLink antibody-drug conjugate (ADC) platform. 14 May 2019
The US Food and Drug Administration has granted Breakthrough Therapy designation to Pomalyst (pomalidomide) for the treatment of patients with human immunodeficiency virus (HIV)-positive Kaposi sarcoma who have previously received systemic chemotherapy, as well as patients with HIV‐negative Kaposi’s sarcoma. 14 May 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024